More than 70 years, androgen-deprivation therapy has been the backbone of treatment for metastatic prostate cancer. In this publication synopsis, the authors assessed whether concomitant treatment of ADT plus docetaxel would result in overall survival in patients with metastatic prostate cancer Vs ADT alone. In the 1940s, regressions of metastatic prostate cancer was first documented and achieved with surgical castration. Later, androgen-deprivation therapy (ADT) became the center point of therapy.
Efforts to improve the efficacy or decrease the treatment burden of ADT have included the use of anti-androgens alone, intermittent dosing of ADT, and the use of an antiandrogen combined with medical or surgical castration. There was a 3 percentage points increase in survival at 5 years with concurrent use of non-steroidal antiandrogen at the time of initiation of ADT. However, most…
